Zanubrutinib-Rituximab Cuts Progression Risk 43 Percent in Frontline Mantle Cell Lymphoma in Phase 3 MANGROVE Trial
BeOne Medicines' chemo-free BRUKINSA plus rituximab regimen met its primary endpoint against bendamustine-rituximab in untreated mantle cell lymphoma.
Overview
BeOne Medicines said on June 30, 2026, that its Phase 3 MANGROVE trial met its primary endpoint, with the BTK inhibitor zanubrutinib (marketed as BRUKINSA) plus rituximab reducing the risk of progression or death by 43% versus bendamustine plus rituximab in adults with previously untreated mantle cell lymphoma, according to BioSpace. The result positions a chemotherapy-free combination as a potential first-line option for a cancer the company describes as a “rare and typically aggressive (fast-growing) type of B-cell non-Hodgkin lymphoma,” per BioSpace.
What We Know
MANGROVE (also identified as BGB-3111-306 and NCT04002297) is a global, randomized, open-label study that enrolled 510 patients across 176 sites worldwide, according to BioSpace. Reporting from CancerNetwork describes the enrolled population as patients aged 70 or older, or 60 to 69 with comorbidities precluding autologous stem-cell transplantation.
On the primary endpoint of progression-free survival, assessed by an independent review committee, the zanubrutinib arm produced a 43% reduction in the risk of progression or death (HR=0.57; 95% CI, 0.43, 0.76; p<0.0001), according to BioSpace. In the experimental arm, patients received zanubrutinib at 160 mg orally twice daily plus rituximab during the initial treatment period, followed by zanubrutinib monotherapy until disease progression or intolerance, while the comparator arm received bendamustine plus rituximab for six cycles, according to StockTitan. CancerNetwork reports the dosing as zanubrutinib 160 mg orally twice daily with rituximab at 375 mg/m2, against bendamustine at 90 mg/m2 plus rituximab.
Overall survival, a key secondary endpoint, was immature at the time of the analysis, though a strong trend in favor of the zanubrutinib regimen was observed, according to StockTitan. The company said the safety profile of zanubrutinib plus rituximab was consistent with the known safety profile of both medicines, with no new safety signals identified, according to BioSpace.
BeOne framed MANGROVE as the first Phase 3 study of its kind to employ a chemotherapy-free, rituximab maintenance-free approach in first-line MCL, sparing patients approximately two years of infusions, according to StockTitan.
“For patients with newly diagnosed MCL, chemotherapy is currently the default. MANGROVE demonstrates for the first time that BRUKINSA plus rituximab, a chemotherapy-free regimen, can deliver unprecedented improvements in progression-free survival, potentially redefining the treatment paradigm globally,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, according to BioSpace.
Zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitor designed to deliver complete and sustained BTK inhibition, and it is approved in more than 80 markets and has been used to treat over 290,000 patients worldwide, according to BioSpace.
What We Don’t Know
BeOne released topline results only; full trial data, including median progression-free survival and response rates, are to be presented at an upcoming medical meeting, according to CancerNetwork. Because overall survival was immature, it remains unknown whether the progression-free survival advantage will translate into a survival benefit. The company said global regulatory submissions are planned for the second half of 2026, according to BioSpace, but approval timelines and the regulators involved were not detailed.
Analysis
MANGROVE targets the frontline setting for transplant-ineligible patients, a different niche from where BTK-adjacent agents have most recently advanced. The Machine Herald previously reported that the FDA granted sonrotoclax accelerated approval as the first BCL-2 inhibitor for relapsed or refractory mantle cell lymphoma; MANGROVE instead tests a BTK inhibitor as initial therapy. If regulators accept the data, the trial would extend the case for replacing upfront chemotherapy in a disease where treatment has long centered on chemoimmunotherapy, though confirmation of a survival benefit and the full efficacy dataset remain outstanding.